Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patent in Japan
June 13, 2023 07:00 ET
|
Salipro Biotech AB
Salipro Biotech obtains granted patent in Japan, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets, including GPCRs,...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07, 2023 08:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics to Present at Jefferies Healthcare Conference
May 31, 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
May 25, 2023 16:30 ET
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
May 18, 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
May 12, 2023 02:30 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023 16:30 ET
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023 16:30 ET
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy
March 15, 2023 04:00 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical stage, international biopharmaceutical company focused on targeting G Protein Coupled...
Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
March 14, 2023 20:05 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...